| Korean Post-marketing Surveillance for Xeljanz XR (NCT04876781) | Pfizer | 2022-01-12 |
| Lorlatinib Continuation Study (NCT05144997) | Pfizer | 2021-12-28 |
| Crizotinib Continuation Clinical Study (NCT05160922) | Pfizer | 2021-12-27 |
| Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia (NCT05116046) | Pfizer | 2021-12-24 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (NCT05228470) | Pfizer | 2021-12-21 |
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea (NCT05132101) | Pfizer | 2021-12-20 |
| An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study (NCT05192200) | Pfizer | 2021-12-20 |
| Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m (NCT05141708) | Pfizer | 2021-12-17 |
| Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy (NCT05198245) | Pfizer | 2021-12-15 |
| Latin American Real-world Study in Acute Leukemia (NCT05166135) | Pfizer | 2021-12-10 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises (NCT04927247) | Pfizer | 2021-12-09 |
| A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting (NCT05478590) | Pfizer | 2021-11-22 |
| Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants (NCT05107492) | Pfizer | 2021-11-19 |
| Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors (NCT05145127) | Pfizer | 2021-11-17 |
| A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis (NCT05195814) | Pfizer | 2021-11-15 |
| Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults (NCT06033612) | Pfizer | 2021-11-12 |
| Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants (NCT05129475) | Pfizer | 2021-11-12 |
| A Study of PF-07258669 In Healthy Adult Participants (NCT05113940) | Pfizer | 2021-11-08 |
| A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis (NCT04915950) | Pfizer | 2021-11-03 |
| Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide (NCT05097716) | Pfizer | 2021-11-02 |
| Post Marketing Surveillance (PMS) Study of Cresemba in Korea. (NCT04744454) | Pfizer | 2021-10-28 |
| MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (NCT05090566) | Pfizer | 2021-10-27 |
| STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS (NCT05093205) | Pfizer | 2021-10-25 |
| A Target Occupancy Study With Ritlecitinib. (NCT05128058) | Pfizer | 2021-10-22 |
| Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age (NCT05096208) | Pfizer | 2021-10-21 |
| A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants (NCT05067439) | Pfizer | 2021-10-21 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537) | Pfizer | 2021-10-20 |
| Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma (NCT04987944) | Pfizer | 2021-10-18 |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (NCT05067972) | Pfizer | 2021-10-07 |
| A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (NCT05014412) | Pfizer | 2021-10-07 |
| Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants (NCT05050682) | Pfizer | 2021-10-07 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises (NCT04935879) | Pfizer | 2021-10-04 |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (NCT05020236) | Pfizer | 2021-10-04 |
| Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection (NCT04927312) | Pfizer | 2021-10-01 |
| Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium (NCT05116267) | Pfizer | 2021-10-01 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522) | Pfizer | 2021-09-29 |
| Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants (NCT05037409) | Pfizer | 2021-09-28 |
| Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant (NCT05046613) | Pfizer | 2021-09-23 |
| Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules (NCT04967443) | Pfizer | 2021-09-22 |
| PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants (NCT05064800) | Pfizer | 2021-09-21 |
| Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants (NCT05032950) | Pfizer | 2021-09-17 |
| A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen (NCT04893798) | Pfizer | 2021-09-16 |
| Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) (NCT05012865) | Pfizer | 2021-09-14 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza (NCT05052697) | Pfizer | 2021-09-13 |
| Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region (NCT04916509) | Pfizer | 2021-09-13 |
| A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults (NCT05040295) | Pfizer | 2021-09-10 |
| Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis (NCT05061446) | Pfizer | 2021-09-10 |
| A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection (NCT05047601) | Pfizer | 2021-09-09 |
| Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor (NCT05361655) | Pfizer | 2021-09-01 |
| A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery (NCT03804125) | Pfizer | 2021-09-01 |
| Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (NCT05035212) | Pfizer | 2021-08-31 |
| Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea (NCT05022563) | Pfizer | 2021-08-31 |
| Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (NCT04882085) | Pfizer | 2021-08-26 |
| Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). (NCT05011513) | Pfizer | 2021-08-25 |
| COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States (NCT05020145) | Pfizer | 2021-08-25 |
| A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment (NCT03812835) | Pfizer | 2021-08-23 |
| Monitoring Activity And Gait In Children (NCT04823650) | Pfizer | 2021-08-23 |
| Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer (NCT04987931) | Pfizer | 2021-08-20 |
| Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants. (NCT04973826) | Pfizer | 2021-08-20 |
| Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (NCT04881045) | Pfizer | 2021-08-18 |
| Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age (NCT04893811) | Pfizer | 2021-08-18 |
| Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition (NCT04916769) | Pfizer | 2021-08-13 |
| Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis (NCT04624230) | Pfizer | 2021-08-12 |
| A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (NCT04814186) | Pfizer | 2021-07-22 |
| Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants (NCT04962022) | Pfizer | 2021-07-20 |
| Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone (NCT05012644) | Pfizer | 2021-07-16 |
| EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 (NCT04960202) | Pfizer | 2021-07-16 |
| Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir (NCT04962230) | Pfizer | 2021-07-15 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus (NCT04889157) | Pfizer | 2021-07-07 |
| Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants (NCT04863417) | Pfizer | 2021-06-30 |
| Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy (NCT04801329) | Pfizer | 2021-06-29 |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma (NCT04996004) | Pfizer | 2021-06-22 |
| A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults (NCT04916795) | Pfizer | 2021-06-17 |
| Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function. (NCT04909853) | Pfizer | 2021-06-15 |
| 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan (NCT04875533) | Pfizer | 2021-06-14 |
| Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review (NCT04609319) | Pfizer | 2021-06-11 |
| An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK (NCT05394493) | Pfizer | 2021-06-11 |
| A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. (NCT04903093) | Pfizer | 2021-06-04 |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer (NCT05584644) | Pfizer | 2021-05-24 |
| A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD) (NCT04983264) | Pfizer | 2021-05-21 |
| Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP) (NCT04774094) | Pfizer | 2021-05-21 |
| Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 (NCT04887948) | Pfizer | 2021-05-20 |
| A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention (NCT04848220) | Pfizer | 2021-05-20 |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML (NCT04842604) | Pfizer | 2021-05-17 |
| Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California (NCT04848584) | Pfizer | 2021-05-15 |
| Study in Healthy Adults Evaluating PF-07202954 (NCT04857437) | Pfizer | 2021-05-13 |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC (NCT04821622) | Pfizer | 2021-05-12 |
| A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571. (NCT04866225) | Pfizer | 2021-05-11 |
| Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia (NCT04803305) | Pfizer | 2021-05-11 |
| Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine (NCT04743141) | Pfizer | 2021-04-28 |
| The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients (NCT04828993) | Pfizer | 2021-04-28 |
| Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia (NCT04878731) | Pfizer | 2021-04-16 |
| Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) (NCT04856293) | Pfizer | 2021-04-16 |
| Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study. (NCT04748445) | Pfizer | 2021-04-12 |
| Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis (NCT04607837) | Pfizer | 2021-04-12 |
| Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age (NCT04819113) | Pfizer | 2021-04-09 |
| A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) (NCT04721977) | Pfizer | 2021-04-08 |
| A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy (NCT04839393) | Pfizer | 2021-04-05 |
| A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device (NCT04832139) | Pfizer | 2021-03-30 |
| A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention (NCT04804033) | Pfizer | 2021-03-26 |